These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 15720189

  • 1. Chemosensitization by antisense oligonucleotides targeting MDM2.
    Bianco R, Ciardiello F, Tortora G.
    Curr Cancer Drug Targets; 2005 Feb; 5(1):51-6. PubMed ID: 15720189
    [Abstract] [Full Text] [Related]

  • 2. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H, Yu D, Agrawal S, Zhang R.
    Prostate; 2003 Feb 15; 54(3):194-205. PubMed ID: 12518324
    [Abstract] [Full Text] [Related]

  • 3. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms.
    Zhang R, Wang H, Agrawal S.
    Curr Cancer Drug Targets; 2005 Feb 15; 5(1):43-9. PubMed ID: 15720188
    [Abstract] [Full Text] [Related]

  • 4. Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H, Oliver P, Zhang Z, Agrawal S, Zhang R.
    Ann N Y Acad Sci; 2003 Dec 15; 1002():217-35. PubMed ID: 14751837
    [Abstract] [Full Text] [Related]

  • 5. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
    Wang H, Nan L, Yu D, Lindsey JR, Agrawal S, Zhang R.
    Mol Med; 2002 Apr 15; 8(4):185-99. PubMed ID: 12149568
    [Abstract] [Full Text] [Related]

  • 6. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.
    Zhang Z, Wang H, Prasad G, Li M, Yu D, Bonner JA, Agrawal S, Zhang R.
    Clin Cancer Res; 2004 Feb 15; 10(4):1263-73. PubMed ID: 14977824
    [Abstract] [Full Text] [Related]

  • 7. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
    Wang H, Nan L, Yu D, Agrawal S, Zhang R.
    Clin Cancer Res; 2001 Nov 15; 7(11):3613-24. PubMed ID: 11705884
    [Abstract] [Full Text] [Related]

  • 8. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
    Bianco R, Caputo R, Caputo R, Damiano V, De Placido S, Ficorella C, Agrawal S, Bianco AR, Ciardiello F, Tortora G.
    Clin Cancer Res; 2004 Jul 15; 10(14):4858-64. PubMed ID: 15269162
    [Abstract] [Full Text] [Related]

  • 9. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.
    Zhang Z, Li M, Wang H, Agrawal S, Zhang R.
    Proc Natl Acad Sci U S A; 2003 Sep 30; 100(20):11636-41. PubMed ID: 13130078
    [Abstract] [Full Text] [Related]

  • 10. MDM2 oncogene as a target for cancer therapy: An antisense approach.
    Wang H, Zeng X, Oliver P, Le LP, Chen J, Chen L, Zhou W, Agrawal S, Zhang R.
    Int J Oncol; 1999 Oct 30; 15(4):653-60. PubMed ID: 10493945
    [Abstract] [Full Text] [Related]

  • 11. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
    Wang H, Wang S, Nan L, Yu D, Agrawal S, Zhang R.
    Int J Oncol; 2002 Apr 30; 20(4):745-52. PubMed ID: 11894120
    [Abstract] [Full Text] [Related]

  • 12. MDM2 oncogene as a novel target for human cancer therapy.
    Zhang, Wang H.
    Curr Pharm Des; 2000 Mar 30; 6(4):393-416. PubMed ID: 10788589
    [Abstract] [Full Text] [Related]

  • 13. A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer.
    Tortora G, Caputo R, Damiano V, Bianco R, Chen J, Agrawal S, Bianco AR, Ciardiello F.
    Int J Cancer; 2000 Dec 01; 88(5):804-9. PubMed ID: 11072252
    [Abstract] [Full Text] [Related]

  • 14. p53-independent activities of MDM2 and their relevance to cancer therapy.
    Zhang Z, Zhang R.
    Curr Cancer Drug Targets; 2005 Feb 01; 5(1):9-20. PubMed ID: 15720185
    [Abstract] [Full Text] [Related]

  • 15. Growth reduction of a xenotransplanted human soft tissue sarcoma by MDM2 antisense therapy via implanted osmotic minipumps.
    Würl P, Bartel F, Meye A, Kappler M, Bache M, Schmidt H, Schönfelder M, Taubert H.
    Int J Oncol; 2002 May 01; 20(5):1087-93. PubMed ID: 11956608
    [Abstract] [Full Text] [Related]

  • 16. Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme.
    Prasad G, Wang H, Agrawal S, Zhang R.
    Anticancer Res; 2002 May 01; 22(1A):107-16. PubMed ID: 12017271
    [Abstract] [Full Text] [Related]

  • 17. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
    Tisato V, Voltan R, Gonelli A, Secchiero P, Zauli G.
    J Hematol Oncol; 2017 Jul 03; 10(1):133. PubMed ID: 28673313
    [Abstract] [Full Text] [Related]

  • 18. Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation.
    Mu Z, Hachem P, Agrawal S, Pollack A.
    Prostate; 2004 Aug 01; 60(3):187-96. PubMed ID: 15176048
    [Abstract] [Full Text] [Related]

  • 19. Novel MDM2 p53-independent functions identified through RNA silencing technologies.
    Zhang Z, Wang H, Li M, Rayburn E, Agrawal S, Zhang R.
    Ann N Y Acad Sci; 2005 Nov 01; 1058():205-14. PubMed ID: 16394138
    [Abstract] [Full Text] [Related]

  • 20. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage.
    Chen L, Agrawal S, Zhou W, Zhang R, Chen J.
    Proc Natl Acad Sci U S A; 1998 Jan 06; 95(1):195-200. PubMed ID: 9419352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.